National XXXX Education Program Adult Treatment Panel III guidelines and @entity28 : implications for Canada.

@entity855 @entity28 @entity1 @entity165
BACKGROUND: The National @entity165 Education Program Adult Treatment Panel ( @entity855 ) III recommendations incorporate new evidence for treating elevated low-density lipoprotein @entity165 . OBJECTIVES: Comparisons between the prevalence of drug-eligible Canadians under the old @entity855 II and the new @entity855 III guidelines were made, and the impact of @entity28 on current and future drug eligibility was explored using various models. METHODS: @entity1 from the Canadian Heart Health Surveys (1986 to 1992; n=17,728; 20 to 74 years of age) were assigned to therapeutic lifestyle change or drug-eligible groups in the event of elevated low-density lipoprotein @entity165 . Body mass index was used to classify @entity1 as having normal weight, or as being overweight or @entity28 . The prevalence of overweight and @entity28 status for 2001, 2006 and 2011 were projected from past trends by linear regression. Population attributable risk was used to model reductions or increases in the prevalence of @entity28 in drug-eligible @entity1 using several nationally representative population health surveys. RESULTS: In 2001, an additional 1.1 million Canadians were drug-eligible under @entity855 III (16.0% of @entity1 , 9.5% of @entity1 ), compared with @entity855 II (7.7% of @entity1 , 7.7% of @entity1 ). Drug eligibility was elevated in overweight @entity1 ( @entity1 : OR=1.87 [1.51 to 2.31]; @entity1 : OR=1.60 [1.13 to 2.28]) and the @entity28 ( @entity1 : OR=2.86 [1.86 to 4.38]; @entity1 : OR=2.28 [1.63 to 3.18]) versus normal weight @entity1 . The population attributable risk was higher in @entity1 (overweight 22.6%, @entity28 11.5%) than in @entity1 (overweight 9.4%, @entity28 9.2%). IMPLICATIONS: A 10% reduction in overweight and @entity28 prevalence could have prevented 69,530 cases of drug eligibility in 2001. On the other hand, by 2011 over one million Canadians will be drug-eligible because of an elevated body mass index, if the recent trends in overweight and @entity28 status continue.
